- |||||||||| FH-MagIC TCR-T / Fred Hutchinson Cancer Center, SignalOne Bio
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: ATTAMAGE-A1: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 13, 2022
P1/2, N=1, Terminated,
N=18 --> 1 | Trial completion date: Apr 2023 --> Aug 2022 | Suspended --> Terminated | Trial primary completion date: Apr 2023 --> Aug 2022; Terminated due to slow accrual.
- |||||||||| FH-MagIC TCR-T / Fred Hutchinson Cancer Center, SignalOne Bio
Trial completion date, Trial suspension, Trial primary completion date, Metastases: ATTAMAGE-A1: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (clinicaltrials.gov) - May 27, 2022
P1/2, N=18, Suspended,
N=18 --> 1 | Trial completion date: Apr 2023 --> Aug 2022 | Suspended --> Terminated | Trial primary completion date: Apr 2023 --> Aug 2022; Terminated due to slow accrual. Trial completion date: Dec 2024 --> Apr 2023 | Recruiting --> Suspended | Trial primary completion date: Dec 2024 --> Apr 2023
- |||||||||| FH-MagIC TCR-T / Fred Hutchinson Cancer Center, SignalOne Bio
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: ATTAMAGE-A1: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (clinicaltrials.gov) - May 17, 2021
P1/2, N=18, Recruiting,
Initiation date: Dec 2021 --> Jul 2021 Trial completion date: Jun 2024 --> Dec 2024 | Initiation date: May 2021 --> Dec 2021 | Trial primary completion date: Jun 2024 --> Dec 2024
|
